UBQLN1 Inhibition reduces MASH progression through downregulating SIKE/p38 MAPK pathway in hepatocyte

Key Points

• This research aims to evaluate the role of UBQLN1 in MASH progression and its implications for therapy.
• Examined the effects of UBQLN1 inhibition on MASH progression
• Analyzed the regulation of SIKE and p38 MAPK pathways in hepatocytes
• Developed a targeted delivery system using RBC-EVs for therapeutic applications.
• UBQLN1 inhibition significantly reduced MASH progression
• Downregulation of the SIKE/p38 MAPK pathway was observed
• The RBC-EVs-targeted delivery system shows potential for effective MASH therapy.